Stage Information for Cervical Cancer
Note: This Stage Information section has been updated to include information from the seventh edition (2010) of the American Joint Committee on Cancer's AJCC Cancer Staging Manual. The PDQ Adult Treatment Editorial Board, which is responsible for maintaining this summary, is currently reviewing the new staging categories to determine whether additional changes need to be made to other parts of the summary. Any necessary changes will be made as soon as possible.
Cervical carcinoma has its origins at the squamous-columnar junction whether in the endocervical canal or on the portion of the cervix. The precursor lesion is dysplasia or carcinoma in situ (cervical intraepithelial neoplasia [CIN]), which can subsequently become invasive cancer. This process can be quite slow. Longitudinal studies have shown that in untreated patients with in situ cervical cancer, 30% to 70% will develop invasive carcinoma over a period of 10 to 12 years. However, in about 10% of patients, lesions can progress from in situ to invasive in a period of less than 1 year. As it becomes invasive, the tumor breaks through the basement membrane and invades the cervical stroma. Extension of the tumor in the cervix may ultimately manifest as ulceration, exophytic tumor, or extensive infiltration of underlying tissue including bladder or rectum.
In addition to local invasion, carcinoma of the cervix can spread via the regional lymphatics or bloodstream. Tumor dissemination is generally a function of the extent and invasiveness of the local lesion. While cancer of the cervix generally progresses in an orderly manner, occasionally a small tumor with distant metastasis is seen. For this reason, patients must be carefully evaluated for metastatic disease.
Pretreatment surgical staging is the most accurate method to determine the extent of disease.[1] Because there is little evidence to demonstrate overall improved survival with routine surgical staging, the staging usually should be performed only as part of a clinical trial. Pretreatment surgical staging in bulky but locally curable disease may be indicated in select cases when a nonsurgical search for metastatic disease is negative. If abnormal nodes are detected by computed tomography scan or lymphangiography, fine-needle aspiration should be negative before a surgical staging procedure is performed.
Definitions of TNM and FIGO
The American Joint Committee on Cancer (AJCC) and the F�deration Internationale de Gyn�cologie et d'Obst�trique (FIGO) have designated staging to define cervical cancer.[2,3] The definitions of the AJCC's T, N, and M categories correspond to the stages accepted by FIGO. Both systems are included for comparison.
Table 1. Primary Tumor (T)a
| TNM Categories | FIGO Stages | � |
| TX | � | Primary tumor cannot be assessed. |
| T0 | No evidence of primary tumor. | |
| Tisb | Carcinoma in situ (preinvasive carcinoma). | |
| T1 | I | Cervical carcinoma confined to uterus (extension to corpus should be disregarded). |
| T1ac | IA | Invasive carcinoma diagnosed only by microscopy. Stromal invasion with a maximum depth of 5.0 mm measured from the base of the epithelium and a horizontal spread of ?7.0 mm. Vascular space involvement, venous or lymphatic, does not affect classification. |
| T1a1 | IA1 | Measured stromal invasion ?3.0 mm in depth and ?7.0 mm in horizontal spread. |
| T1a2 | IA2 | Measured stromal invasion >3.0 mm and ?5.0 mm with a horizontal spread of ?7.0 mm. |
| T1b | IB | Clinically visible lesion confined to the cervix or microscopic lesion >T1a/IA2. |
| T1b1 | IB1 | Clinically visible lesion ?4.0 cm in greatest dimension. |
| T1b2 | IB2 | Clinically visible lesion >4.0 cm in greatest dimension. |
| T2 | II | Cervical carcinoma invades beyond uterus but not to pelvic wall or to lower third of vagina. |
| T2a | IIA | Tumor without parametrial invasion. |
| T2a1 | IIA1 | Clinically visible lesion ?4.0 cm in greatest dimension. |
| T2a2 | IIA2 | Clinically visible lesion >4.0 cm in greatest dimension. |
| T2b | IIB | Tumor with parametrial invasion. |
| T3 | III | Tumor extends to pelvic wall and/or involves lower third of vagina, and/or causes hydronephrosis or nonfunctioning kidney. |
| T3a | IIIA | Tumor involves lower third of vagina, no extension to pelvic wall. |
| T3b | IIIB | Tumor extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney. |
| T4 | IVA | Tumor invades mucosa of bladder or rectum, and/or extends beyond true pelvis (bullous edema is not sufficient to classify a tumor as T4). |
WebMD Public Information from the National Cancer Institute
